Genomic Health Accelerates Timeline for Prostate Cancer Test
January 10, 2011
Genomic Health Accelerates Timeline for Prostate Cancer Test
The firm also said that Israeli insurance firm Clalit has agreed to provide reimbursement for the Oncotype Dx colon cancer test.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- QUASAR Study Shows Oncotype DX Gauges Colon Cancer Recurrence Risk, Doesn't Predict Treatment Benefit
November 9, 2011 / Pharmacogenomics Reporter - After Profitable Year, Genomic Health to Invest in New Products, Overseas Market, Next-Gen Sequencing
February 16, 2011 / Pharmacogenomics Reporter - TGen, Genomic Health ID Potential Oxaliplatin Response Genes; Findings May Enhance Colon Cancer Test
January 19, 2011 / Pharmacogenomics Reporter - Genomic Health Updates Investors on Timeline for DCIS, Colon Cancer, Prostate Cancer Tests
September 29, 2010 / Pharmacogenomics Reporter - With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter